...
首页> 外文期刊>Pain. >Single intrathecal injections of dynorphin A or des-Tyr-dynorphins produce long-lasting allodynia in rats: blockade by MK-801 but not naloxone.
【24h】

Single intrathecal injections of dynorphin A or des-Tyr-dynorphins produce long-lasting allodynia in rats: blockade by MK-801 but not naloxone.

机译:鞘内注射强啡肽A或des-Tyr-强啡肽会在大鼠中产生持久性异常性疼痛:被MK-801阻滞,但不受纳洛酮的阻滞。

获取原文
获取原文并翻译 | 示例
           

摘要

Neuropathic pain states are accompanied by increased sensitivity to both noxious and non-noxious sensory stimuli, characterized as hyperalgesia and allodynia, respectively. In animal models of neuropathic pain, the presence of hyperalgesia and allodynia are accompanied by neuroplastic changes including increased spinal levels of substance P, cholecystokinin (CCK), and dynorphin. N-Methyl-D-aspartate (NMDA) receptors appear to be involved in maintaining the central sensitivity which contributes to neuropathic pain. In addition to its opioid activities, dynorphin has been suggested to act at the NMDA receptor complex. In an attempt to mimic the increased levels of spinal dynorphin seen in animal models of neuropathic pain, rats received a single intrathecal (i.t.) injection of dynorphin A(1-17), dynorphin A(1-13), dynorphin A(2-17) or dynorphin A(2-13) through indwelling catheters. Tactile allodynia was determined by measuring response threshold to probing with von Frey filaments. Dynorphin A(1-17) administration evoked significant and long-lasting tactile allodynia (i.e. > 60 days). Likewise, the i.t. administration of dynorphin A(1-13) or dynorphin A(2-17) or dynorphin A(2-13) also produced long-lasting tactile allodynia. Intrathecal pretreatment, but not post-treatment, with MK-801 prevented dynorphin A(1-17)-induced development of allodynia; i.t. administration of MK-801 alone had no effect on responses to tactile stimuli. In contrast, i.t. pretreatment with naloxone did not affect the development of tactile allodynia induced by dynorphin A(1-17) or alter sensory threshold when given alone. These results demonstrate that a single dose of dynorphin A, or its des-Tyr fragments, produces long-lasting allodynia which may be irreversible in the rat. Further, this effect appears to be mediated through activation of NMDA, rather than opioid, receptors. While the precise mechanisms underlying the development and maintenance of the allodynia is unclear, it seems possible that dynorphin may produce changes inthe spinal cord, which may contribute to the development of signs reminiscent of a "neuropathic' state. Given that levels of dynorphin are elevated following nerve injury, it seems reasonable to speculate that dynorphin may have a pathologically relevant role in neuropathic pain states.
机译:神经性疼痛状态伴随着对伤害性和非伤害性感觉刺激的敏感性增加,分别以痛觉过敏和异常性疼痛为特征。在神经性疼痛的动物模型中,痛觉过敏和异常性疼痛的出现伴随着神经塑性变化,包括脊柱中P物质,胆囊收缩素(CCK)和强啡肽的水平升高。 N-甲基-D-天冬氨酸(NMDA)受体似乎参与维持中枢敏感性,这有助于神经性疼痛。除了其阿片样物质的活性,强啡肽还被认为对NMDA受体复合物起作用。为了模拟在神经性疼痛动物模型中观察到的脊髓强啡肽水平升高,大鼠接受了鞘内注射强啡肽A(1-17),强啡肽A(1-13),强啡肽A(2-) 17)或强啡肽A(2-13)通过留置导管。通过测量对冯·弗雷丝探测的反应阈值来确定触觉异常性疼痛。强啡肽A(1-17)引起明显且持久的触觉异常性疼痛(即> 60天)。同样,i.t。强啡肽A(1-13)或强啡肽A(2-17)或强啡肽A(2-13)的使用也可产生持久的触觉异常性疼痛。鞘内预处理,但不是后处理,用MK-801阻止强啡肽A(1-17)诱导的异常性疼痛的发展;它。单独施用MK-801对触觉刺激没有影响。相反,i.t。纳洛酮预处理不会影响强啡肽A(1-17)诱导的触觉异常性疼痛的发展,也不会改变单独给予时的感觉阈值。这些结果表明,单剂量强啡肽A或其des-Tyr片段会产生持久的异常性疼痛,这在大鼠中可能是不可逆的。此外,该作用似乎是通过NMDA而不是阿片样物质受体的活化来介导的。虽然尚不清楚异常性疼痛的发生和维持的确切机制,但强啡肽可能会在脊髓中产生变化,这可能有助于让人联想到“神经性”状态的体征。神经损伤后,似乎有理由推测强啡肽在神经性疼痛状态中可能与病理相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号